Introduction {#s1}
============

The interleukin (IL)-17 family includes six structure-related cytokines (A--F; [Figure 1](#F1){ref-type="fig"}). IL-17A, the first discovered member of the IL-17 family, was cloned in 1993 and originally termed as cytotoxic T lymphocyte antigen 8 ([@B1]). Unexpectedly, IL-17A shares sequence homology with an open reading frame in *Herpesvirus saimiri* ([@B1]). IL-17-binding receptor (IL-17RA) was subsequently identified in 1995 ([@B2]). Screens for homologous genes caused the discovery of other five highly conserved homologous members of the IL-17 family (IL-17B to IL-17F) ([@B3], [@B4]). IL-17F shows high homology with IL-17A, whereas IL-17E (also known as IL-25) shows only 16% sequence homology with IL-17A ([@B5], [@B6]). Analogous to platelet-derived growth factor and nerve growth factor, these molecules adopt a cysteine knot fold ([@B3], [@B4]). IL-17B and IL-17D have been shown to induce the secretion of chemokines and proinflammatory cytokines, but their biological actions remain scarcely explored ([@B7]--[@B9]). In contrast, the proinflammatory properties of IL-17A and IL-17F are well characterized ([@B5], [@B6]). Additionally, the IL-17 receptor family includes five cytokine receptors (IL-17RA to IL-17RE) characterized by a shared cytoplasmic motif named the SEF/IL-17R (SEFIR) ([@B5]).

![Timeline of advances in the research on interleukin-17 cytokine.](fimmu-11-01558-g0001){#F1}

IL-17A expression was first reported in T helper (Th) cells ([@B10], [@B11]). IL-17A is recognized as a hallmark molecule of CD4^+^ T helper 17 (Th17) cells, which characteristically express the transcription factor RAR-related orphan receptor γ (RORγt) ([@B12]). The development of Th17 cells, including clonal expansion and phenotype stabilization of IL-17A production, is dependent on IL-23 ([@B13]). Mechanistically, IL-23 expands the Th17 cell population by upregulating signal transducers and activators of transcription (STAT)-triggered RORγt and subsequent promotion of IL-17A release ([@B14]). Thus, IL-23 is recognized as a potent inducer of IL-17A. Recent studies suggest that the so-called "IL-17/IL-23 axis" is a key element in inflammation and is involved in the immune responses to fungal and bacterial infection and autoimmune diseases ([@B12], [@B13]).

IL-17A can be secreted by other cell subsets, such as γδT cells, cytotoxic CD8^+^ T cells, innate tissue-specific cells, innate lymphoid cells (ILCs), and myeloid cells ([Figure 2](#F2){ref-type="fig"}) ([@B14], [@B15]). IL-17A-mediated inflammation is required for host protection and survival against infection ([@B8], [@B9], [@B16]). IL-17A can also exacerbate fetal inflammatory responses, and has been implicated in immunopathology. IL-17A levels are elevated in various inflammatory conditions, including sepsis, pneumonia, systemic lupus erythematosus, rheumatoid arthritis, allograft rejection, and cancer ([@B17], [@B18]). Here we review the literature on IL-17-driven inflammatory and immune cascades during the development of sepsis.

![Cellular sources and receptors of interleukin-17. Interleukin (IL)-17 family includes isoforms A to F. IL-17 can be induced by a variety of cells including T helper (Th) 17 cells, γδT cells, natural killer T (NKT) cells, group 3 innate lymphoid cells (ILC3s), CD8^+^ (Tc17) cells, neutrophils, microglia, mast cells, myeloid cells in the lung and kidneys, and Paneth cells in the intestine. In addition, antigen-presenting cells (APCs) stimulate the production of IL-17in response to stress proteins, pathogen-associated molecular patterns (PAMPs), or microbial metabolites. IL-17 receptor (IL-17R) family is composed of IL-17RA, IL-17RB, IL-17RC, IL-17RE, as well as IL-17RA and C heterodimeric complex.](fimmu-11-01558-g0002){#F2}

IL-17 Biology {#s2}
=============

Structural Features of IL-17
----------------------------

The IL-17 family contains six isoforms of 20--30 kDa molecular weight and is a group of secreted and glycosylated proteins. All other members of the IL-17 family show 20--55% sequence homology to IL-17A, with IL-17E exhibiting the lowest homology with other family members ([@B8], [@B9]). IL-17A and IL-17F could exist as heterodimers or homodimers and are co-expressed by linked genes ([@B19]). Structurally, IL-17 family proteins have a conserved C-terminus with four cysteine residues, which form intramolecular disulfide bridges ([@B20]).

Production of IL-17
-------------------

IL-17 can be produced by a broad spectrum of cell populations ([Figure 2](#F2){ref-type="fig"}), including Th17 cells, γδT cells, NKT cells, group 3 innate lymphoid cells (ILC3s), CD8^+^ (Tc17) cells, neutrophils, microglia, and mast cells ([@B10], [@B12], [@B15]). IL-23 and RORγt are indispensable for all IL-17-producing cell types ([@B13]).

Th17 cells were first identified in 2005 and were recognized as the primary source of IL-17 ([@B16]). In addition to IL-17, Th17 cells also produce a variety of inflammatory cytokines including granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-21, and IL-22 ([@B16]). Th17-induced responses are implicated in host defense against infections, inflammatory and autoimmune disorders, and tumorigenesis ([@B21]). Other major sources of IL-17 include myeloid cells (e.g., kidneys and lungs) and Paneth cells in the intestinal crypts ([@B8]).

In response to stress proteins, pathogen-associated molecular patterns (PAMPs), or microbial metabolites, antigen-presenting cells (APCs) produce IL-23 and IL-1β to accelerate IL-17 release ([@B8]). IL-17 levels are depended on the particular context, including the pathogen and site and severity of infection ([@B10], [@B12]).

IL-17 Receptor and Its Signal Transduction
------------------------------------------

IL-17 cytokines bind to five cytokine receptors (IL-17RA to IL-17RE, [Figure 2](#F2){ref-type="fig"}) on target cells to drive their biological actions ([@B2], [@B9]). IL-17R is expressed in a variety of cell populations, including keratinocytes, fibroblasts, mesothelial cells, epithelial cells, and leukocytes ([@B9]). All these receptors share a SEFIR domain in the intracellular domain and a fibronectin III-like region in the extracellular region ([@B10]). IL-17RA is a shared receptor for different IL-17 isoforms. IL-17 cytokines can trigger signals via an IL-17RA/IL-17RC receptor complex. IL-17RB and IL-17RE serve as the specific receptors for IL-17B and IL-17RA/IL-17RB heterodimeric complex, respectively ([@B9]). IL-17A and IL-17F act through the same IL-17RA/IL-17RC receptor complex.

Studies suggest that IL-17RD also drives IL-17-mediated signaling, but the ligand of IL-17RD remains unknown ([@B21]).

IL-17A/IL-17C interacts with IL-17R to stimulate inflammatory reactions via activation of mitogen-activated protein kinase (MAPK), nuclear factor-kappa B (NF-κB), CCAAT/enhancer-binding protein (C/EBP), Janus kinase (JAK)/phosphatidylinostitol 3-kinase (PI3K), and JAK/STAT signaling ([Figure 3](#F3){ref-type="fig"}) ([@B22]--[@B25]). IL-17A can also signal through Toll-IL-1 receptor (TIR)-domain-containing adapter-inducing interferon-β (TRIF), myeloid differentiation primary response gene 88 (MyD88), and the adaptor proteins ([@B9], [@B21]). Interestingly, IL-17A does not induce IL-17R cascades in embryonic fibroblasts of mice deficient in necrosis factor receptor-associated factor (TRAF)-6, suggesting that TRAF-6 is essential for IL-17A/IL-17R signaling ([@B26]). Furthermore, several studies have identified NF-κB activator 1 (Act1) as a key adapter molecule for TRAF-6 recruitment in the induction of IL-17R signaling ([@B27]).

![Interleukin-17A signaling transduction pathway. In general, all IL-17R members contain a shared and conserved cytoplasmic motif named a SEFIR/SEFEX domain similar to the TIR region in IL-1 receptors and TLRs. Initially, IL-17R signaling triggers the recruitment of Act1, which includes a SEFIR domain and is required for IL-17R-Act1 combination. Subsequently, Act1 can ubiquitinate TRAF6 and E3 ubiquitin ligase. Upon ligand binding, TRAF2/5, TRAF4, and TRAF6 can be engaged by Act1 and stabilize mRNAs by activating RNA-binding proteins such as Arid5a, HuR, and DDX3X. IL-17A promotes the activities of AP1 and MAPK, as well as δ transcription factors and C/EBPβ activation (CBAD). IL-17A also accelerates IκBα degradation and IKK activation, thereby inducing NF-κB signaling. NF-κB in turn improves IL-17A-mediated proinflammatory and anti-microbial responses. IL-17A/NF-κB signal transduction can trigger a feedback loop that controls overactivation of the NF-κB cascade. TRAF, TNF-receptor associated factor; SEFIR, similar expression of fibroblast growth factor and IL-17Rs; SEFEX, SEFIR extension; TLRs, Toll-like receptors; C/EBPβ, CCAAT/enhancer-binding protein β; CBAD, C/EBPβ activation domain; AP1, activator protein 1; MAPK, mitogen-activated protein kinase; NF-κB, nuclear factor κB; IKK, IκBα degradation and IκB kinase; JNK, Janus kinase; HuR, human antigen R.](fimmu-11-01558-g0003){#F3}

Functions of IL-17
------------------

### IL-17A

IL-17A is the most studied member of the IL-17 family. IL-17A interacts with several mediators \[e.g., GM-CSF, interferon (IFN)-γ, IL-22, IL-1β, tumor necrosis factor-α (TNF-α)\] to exert its proinflammatory effect ([@B15]).

In general, IL-17A-mediated downstream pathways induce the production of inflammatory molecules, chemokines, antimicrobial peptides (AMPs), and remodeling proteins ([Figure 4](#F4){ref-type="fig"}). IL-17A elicits crucial impacts on host defense, cell trafficking, immune modulation, and tissue repair, with a key role in the induction of innate immune defenses. IL-17A stimulates non-hematopoietic cells (e.g., epithelial cells) and then acts alone or synergistically with additional proinflammatory mediators to promote chemokine production \[e.g., chemokine (C-C motif) ligand (CCL)-20, granulocyte-colony stimulating factor (G-CSF), C-X-C motif ligand (CXCL)-1, CXCL-2, and CXCL-8\], thereby attracting myeloid cells to inflammatory sites ([@B28]). IL-17A also stimulates the release of IL-2 from Th cells, which in turn expands regulatory T cells ([@B5]). IL-17A also promotes the secretion of AMPs (e.g., β-defensins, calgranulin, S100A8, and lipocalin-2) from macrophages and neutrophils in response to acute pathogen invasion ([@B21]). Moreover, IL-17A may induce other AMPs and proteins, including inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) ([@B29]).

![Summary of interleukin-17A functions. IL-17A-driven signaling drives several effector functions including chemokine induction, cell infiltration, antimicrobial peptide (AMP) production, and tissue barrier function and remodeling. Firstly, IL-17A triggers production of chemokine (C-C motif) ligand (CCL)-20 and granulocyte-colony stimulating factor (G-CSF), which act in synergy with other proinflammatory cytokines (e.g., TNF-α, IL-6, and IL-1) to induce neutrophil recruitment. IL-17A regulates the release of various chemokines. For example, chemokine (C-X-C motif) ligand (CXCL)-1, CXCL-2, CXCL-5, and granulocyte-macrophage colony-stimulating factor (GM-CSF) can improve neutrophil response. CCL7, CCL2, CXCL-9, CXCL-10, and CXCL-20 modulate the activities of monocytes and dendritic cells (DCs). Secondly, IL-17A stimulate macrophages and neutrophils to produce AMPs including β-defensins, lipocalins, S100 proteins, lactoferrins, and regenerating (REG) proteins, helping to kill bacteria. Thirdly, IL-17A signaling maintains tight junctions in mucosal tissues through formation of several acute phase proteins. IL-17A also participates in remodeling of the airway vascular, splenic vein, central nervous system (CNS), and heart tissues.](fimmu-11-01558-g0004){#F4}

IL-17A is critical for maintaining mucosal barrier integrity and function by increasing tight junctions and inducing acute phase proteins ([@B8], [@B9]). IL-17A helps to orchestrate airway vascular remodeling through Th17 cell responses in pulmonary inflammation ([@B8]). Similarly, IL-17A has been shown to upregulate endothelial tissue factor and is involved in splenic vein remodeling ([@B30]). Additionally, IL-17A plays a key role in repair and remodeling of other tissues such as ventricular tissue in myocardial infarction and bone resorption ([@B31]).

### Roles of IL-17B Through IL-17F

IL-17B was originally identified as a proinflammatory mediator that accelerates neutrophil recruitment and migration ([@B7]). IL-17B inhibits IL-25 signaling and attenuates mucosal inflammation ([@B5]). IL-17B promotes the proliferation and survival of cancer cells in animal models ([@B7]), and increased IL-17B levels are linked to poor outcome in patients with several types of cancers (e.g., breast, lung, and pancreatic) ([@B5]).

IL-17C can be produced by several non-immune cells (e.g., epithelial cells, cutaneous neurons, and keratinocytes) and provide host protection in the intestine, skin, and the nervous system ([@B5]). For example, IL-17C released from epithelial cells maintains barrier integrity in an autocrine manner following epithelial damage ([@B8]). Emerging evidence indicates that IL-17C is sufficient to promote growth and survival of nerves and protect peripheral neurons during reactivation of herpes simplex virus-2 ([@B6]).

IL-17D is the least studied cytokine in the IL-17 family. Similar to other isoforms, IL-17D triggers secretion of diverse inflammatory cytokines such as GM-CSF, IL-6, and IL-8. Several studies have shown markedly increased IL-17D in viral infection and tumors ([@B7]).

Similar to IL-17A, IL-17E acts as a "mucosal barrier" molecule that confers immunity against parasitic infections ([@B8]). Thymic epithelial cells promote IL-17E production and host defenses via T cell receptor development of type 2 innate-like lymphoid cells (iNKT-2) ([@B32]). IL-17E is distinct from other member of the IL-17 family. IL-17E drives stromal cells, type 2 T helper (Th2) cells, epithelial cells, and ILC2s ([@B5]). It also accelerates production of thymic stromal lymphopoietin (TSLP), IL-13, IL-5, IL-4, and IL-13, and lowers the levels of IL-23, IL-6, and IL-1 ([@B9]). IL-17E is involved in the pathogenesis of parasitic and fungal infections, allergy, and autoimmune disorders. For example, large amounts of IL-17E are produced following infection with the parasitic helminth *Nippostrongylus* or *Aspergillus*. Furthermore, IL-17E-mediated responses depend on the airway epithelium, mast cells, eosinophils, and Th2 cells, thereby contributing to the immunopathogenesis of asthma ([@B33]).

IL-17F and IL-17A share similarities in receptors, signaling, function, and cellular sources. Similar to IL-17A, IL-17F plays a critical role in inflammatory responses and mucosal barrier maintenance ([@B4]).

Roles of IL-17 in the Development of Sepsis {#s3}
===========================================

IL-17 in Host Defense During Sepsis
-----------------------------------

Sepsis is caused by improper inflammatory and immune responses due to the inability of the host defenses to contain infection ([@B34]). As a crucial part of host immunity, IL-17A confers powerful protective effects against infections caused by bacteria, fungi, virus, and parasites ([Figure 5](#F5){ref-type="fig"}); ([Table 1](#T1){ref-type="table"}) ([@B16], [@B17]). Increased circulating levels of IL-17A are observed in experimental and human sepsis ([@B16], [@B17]). A series of clinical studies have demonstrated that high serum IL-17A levels are associated with greater risk of sepsis, suggesting that this cytokine might serve as a novel predictor of sepsis progression as well as an attractive therapeutic target ([@B34]).

![Protective and pathological roles of interleukin-17A in the pathogenesis of sepsis. IL-17A triggers various immune cells (e.g., neutrophils, lymphocytes, macrophages, monocytes, and B cells) to boost innate, adaptive, and humoral responses with different actions. Meanwhile, IL-17A signaling exhibits a strong protective effect against diverse infections (e.g., bacterial, fungal, viral, and parasitic infections) through promotion of host defenses and cytokine release. In addition, IL-17A may induce pathologic immune responses and then impair organ functions, which result in pathological alterations such as acute lung injury (ALI)/acute respiratory distress syndrome (ARDS), acute kidney injury (AKI), hepatic dysfunction, immune dysfunction, gut barrier dysfunction, and cardiomyocyte dysfunction.](fimmu-11-01558-g0005){#F5}

###### 

Summary of studies on the pathophysiological significances of IL-17 in sepsis.

  **System**   **Year**   **Authors**         **Clinical observations or conclusions**                                                                                                                                                                                           **References**
  ------------ ---------- ------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------
  Mice         2003       Tian et al.         CD4^+^ T cells mediated abscess formation in intra-abdominal sepsis by an IL-17-dependent mechanism                                                                                                                                ([@B35])
               2007       Shibata et al.      Resident Vδ1^+^ γδ T cells controlled early infiltration of neutrophils after *Escherichia coli* infection via IL-17 production                                                                                                    ([@B36])
               2008       Flierl et al.       γδ T cell-derived IL-17 promoted high levels of proinflammatory mediators and bacteremia, increasing lethality                                                                                                                     ([@B37])
               2009       Freitas et al.      IL-17 enhanced the microbicidal activity of migrating neutrophils in sepsis induced by cecal ligation and puncture                                                                                                                 ([@B38])
               2010       Kasten et al.       IL-17 production by γδ T cells accelerated neutrophil recruitment in a sepsis model                                                                                                                                                ([@B39])
               2012       Joshi et al.        Immunization with *Staphylococcus aureus* iron regulated surface determinant B conferred protection via Th17/IL-17 pathway                                                                                                         ([@B40])
               2012       Ogiku et al.        IL-17A played a pivotal role in polymicrobial sepsis according to studies using IL-17 knockout mice                                                                                                                                ([@B41])
               2013       Bosmann et al.      Plasma concentrations of IL-17, IL-17F, and the IL-17AF heterodimer were obviously increased in mice after cecal ligation and puncture                                                                                             ([@B42])
               2014       Shimura et al.      IL-17, but not IL-17F or IL-25, was important to lipopolysaccharide-induced endotoxin shock; Myeloid cells and eosinohils, but not Th17 cells, was a source of IL-17 during endotoxin shock.                                       ([@B43])
               2014       Jing et al.         Recombinant IL-17 rescued impaired host defense in *cxcl1^−/−^* mice; CXCL1 was important for IL-17 production via Th17 differentiation                                                                                            ([@B44])
               2014       Cauvi et al.        Elevated expression of IL-23/IL-17 pathway-related mediators correlated with exacerbation of pulmonary inflammation following polymicrobial sepsis                                                                                 ([@B45])
               2015       Costa et al.        Murine IL-17^+^Vγ4 T lymphocytes accumulated in the lungs and played a protective role in severe sepsis                                                                                                                            ([@B46])
               2015       Meng et al.         Activation of TLR2 by disseminated Gram-positive bacteria induced sustained upregulation of IL-17A and IL-6                                                                                                                        ([@B47])
               2016       Zhao et al.         Mice that completely lacked IL-17 failed to accumulate and activate neutrophils. Lung inflammation was attenuated in IL-17-deficient mice                                                                                          ([@B48])
               2016       Cen et al.          MFG-E8 downregulated IL-17 expression in sepsis by modulating STAT3 activation                                                                                                                                                     ([@B49])
               2016       Wynn et al.         IL-18 administration in sepsis increased IL-17A production by murine intestinal γδ T cells as well as Ly6G^+^ myeloid cells, and blocking IL-17A reduced IL-18-potentiated mortality in both neonatal sepsis and endotoxemia       ([@B50])
               2016       Luo et al.          IL-17A knockout in mice protected against sepsis-associated acute kidney injury                                                                                                                                                    ([@B51])
               2017       Lv et al.           IL-33 attenuated sepsis by inhibiting IL-17 receptor signaling through upregulation of SOCS3                                                                                                                                       ([@B52])
               2015       Szabo et al.        Rapid and rigorous IL-17A production by a distinct subpopulation of effector memory T lymphocytes constituted a novel mechanism of toxic shock syndrome immunopathology                                                            ([@B53])
  Rats         2018       Han et al.          The levels of IL-17A in plasma, lung, and liver gradually increased with time in a sepsis neonatal rat model                                                                                                                       ([@B54])
  Patients     2011       Makada et al.       IL-17A genetic variation was associated with altered susceptibility to Gram-positive infection and mortality in severe sepsis                                                                                                      ([@B55])
               2011       Palumbo et al.      No significant associations were found between IL-6 and IL-17F genotypes and the related cytokine serum levels in burn patients with sepsis                                                                                        ([@B56])
               2015       Wu et al.           Treatment of anti-IL-17 enhanced IL-10 production but decreased IL-12 secretion in stimulated peripheral blood mononuclear cells of healthy controls and patients with severe sepsis                                               ([@B57])
               2015       Paraschos et al.    Patients with multiple injuries showed defective TNF-α, IL-10, IL-17, and IFN-γ responses to a broad panel of bacterial stimuli                                                                                                    ([@B58])
               2016       Maravistsa et al.   IL-17 was the only cytokine produced in high quantities by peripheral blood mononuclear cells and CD4^+^ lymphocytes in patients with septic shock and acute kidney injury                                                         ([@B59])
               2017       Preisser et al.     Increased IL-17 was noted in patients with sepsis-induced acute respiratory distress syndrome; IL-17 antibody administration might relieve acute lung injury symptoms by affecting RORγt levels and modulating the PI3K pathway.   ([@B60])
               2017       Ali et al.          Elevated serum IL-17 increased the susceptibility for septic complications in polytrauma patients, and might be a useful biomarker of such risk                                                                                    ([@B61])

### Bacterial Infection

It is widely accepted that bacterial infections predominantly contribute to the development of sepsis ([@B18]). Interestingly, IL-17A genetic variations influence the risk of gram-positive infection and correlate with short-term mortality in patients with severe sepsis ([@B55]). Studies suggest that IL-17A-mediated signaling orchestrates inflammatory and immune cascades by inducing proinflammatory mediators, thereby participating in preventing bacteria during sepsis ([@B21]).

IL-17A levels are positively associated with tissue bacterial loads in mice infected with *Klebsiella pneumonia* ([@B62]). Physiological levels of IL-17A in type 3 innate lymphoid cells (ILCs) accelerate G-GSF production and neutrophil recruitment, protecting the host against sepsis ([@B15]). Experimental and human sepsis involves impaired neutrophil recruitment and migration, the extent of which is positively associated with disease severity ([@B63]). IL-17A augments the migration and microbicidal activity of neutrophils, as well as mobilization of T lymphocytes ([@B64]). IL-17A improves neutrophil recruitment and bacterial eradication via γδT cells in a murine model of sepsis ([@B36]).

Decreased levels of IL-17A are correlated with increased risk of bacteremia ([@B62]). In IL-17R-deficient mice infected with *Klebsiella pneumoniae*, levels of G-CSF, macrophage inflammatory protein-2 (MIP-2), and chemokines were reduced, contributing to decreased neutrophil infiltration and microbial clearance ([@B62]). In agreement with this observation, IL-17A-deficient mice are also more susceptible to infection by other bacteria, including *Bordetella pertussis, Citrobacter rodentium, Escherichia coli*, and *Staphylococcus aureus* ([@B65], [@B66]). IL-17R-deficient mice showed decreased neutrophil recruitment, augmented infection spread, and exacerbated inflammatory responses following cecal ligation and puncture (CLP) ([@B48]). IL-17A also stimulates epithelial cells to trigger antimicrobial responses against intracellular bacteria such as *Listeria monocytogenes, Mycobacterium bovis Bacillus-Calmette Guérin*, and *Salmonella typhimurium* ([@B67]--[@B69]).

### Fungal Infection

Invasive fungal infection is increasingly frequent in septic patients and correlates with a high risk of mortality ([@B70]). Importantly, IL-17A exerts immunoprotective effects in antifungal defense via induction of AMPs, chemokines, and proinflammatory cytokines ([@B71]). Meanwhile, IL-17A is sufficient to activate NK cells through release of GM-CSF, thereby eliciting its fungicidal activity ([@B72]). IL-17R knockdown increases susceptibility to fungal pathogens during systemic candidiasis ([@B70], [@B73]). Notably, low IL-17A levels are related to impaired host immunity in clinical observation ([@B74]). IL-17A responses are required for controlling infection with fungal pathogens, including *Aspergillus fumigatus, Pneumocystis carinii, Cryptococcus neoformans*, and *Candida albicans* ([@B73]--[@B78]). On the other hand, IL-17C induces lethal inflammation by exacerbating secretion of proinflammatory cytokines, contributing to the development of systemic fungal infection ([@B78]). These paradoxical effects require further investigation.

### Viral Infection

Sepsis often occurs in cases of immunosuppression, when it manifests as an increased susceptibility to opportunistic infections, especially by virus ([@B18]). Several studies have shown that IL-17 promotes host immunity against influenza infection ([@B21]). In mice challenged with influenza virus, lack of IL-17 was associated with increased mortality ([@B79]). Adoptive transfer of IL-17-producing cells protected mice against a lethal dose of influenza virus ([@B80]). Also, IL-17A participates in the immunopathogenesis of influenza A (H1N1)-induced acute lung injury ([@B80]). Likely, IL-17A-mediated response is correlated with disease severity following infections by Epstein-Barr virus (EBV), herpes simplex virus (HSV), respiratory syncytial virus (RSV), vaccinia virus, and hepatitis virus ([@B81], [@B82]). Depletion of IL-17R mitigates inflammation and decreases neutrophil influx, hindering influenza infection ([@B82]). IL-17A neutralization could reduce viral load and mortality during herpes simplex virus infection ([@B82]). Protective or pathological roles of IL-17 during viral infections remain controversial.

### Parasitic Infection

Few studies have examined the potential role of IL-17A in host defense against parasites ([@B5]). Studies suggest that Th17 cells, the major source of IL-17A, could impair host defenses against *Echinococcus granulosus, Leishmania braziliensis, Toxoplasma gondii*, and *Trypanosoma cruzi* ([@B83]--[@B87]). In patients with toxoplasmosis, CD8^+^ and CD4^+^ cells could limit parasitic replication and invasion ([@B86]). High IL-17A levels are detectable in peripheral blood mononuclear cells from patients with *Leishmaniasis* ([@B87]). IL-17R deficiency leads to lower expression of CXCL1 and CXCL2 in the liver and spleen as well as less neutrophil recruitment in *Trypanosoma cruzi*-infected mice ([@B83]). In the case of *Leishmania* infection, IL-17A blockade reduces disease severity in a mouse model ([@B88]). IL-17A antibody neutralization reduces inflammation and improves survival in mice following *Toxoplasma gondii* challenge ([@B86]). Collectively, available evidence supports a pathological role for IL-17 in parasitic infections, but further work is needed to explore whether this depends on the host, parasite, or other factors.

In summary, IL-17 contributes to host protection against diverse infectious organisms during sepsis while inducing hyperinflammation with detrimental outcomes for the host under certain conditions. Further investigation on the role of IL-17 and the interplay with other immune factors needs to be conducted in clinical settings.

IL-17 in Organ Dysfunction Resulted From Sepsis
-----------------------------------------------

Studies have shown that overproduction of IL-17 could exaggerate immune responses, which in turn may lead to impaired organ function ([@B89]) ([Figure 5](#F5){ref-type="fig"}). In line with these observations, elevated levels of IL-17A have been detected in plasma and tissues during sepsis associated with multiple organ damage ([@B37], [@B38], [@B54], [@B56]--[@B58], [@B61]) ([Table 1](#T1){ref-type="table"}).

### Acute Lung Injury or Acute Respiratory Distress Syndrome

Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are early events in the course of sepsis ([@B90]). Neutrophil infiltration plays an integral part in ARDS. IL-17R signaling is proposed to regulate neutrophil trafficking into the lung to maintain host immunity ([@B9]). The addition of recombinant IL-17A into the airway causes the production of chemokines that recruit inflammatory and immune cells ([@B48]). In contrast, IL-17RA or IL-17A knockout decreases CXCL1 and G-CSF levels in the bronchoalveolar lavage fluid of mice ([@B62]). In line with this, hyperproduction of IL-17A is involved in uncontrolled pulmonary inflammation in mice infected with *Haemophilus influenza* ([@B91]). Interestingly, γδT lymphocytes (comprising the Vγ4 T lymphocytes) accumulate in the lungs of septic mice ([@B46]). Surprisingly, administration of anti-Vγ4 monoclonal antibody increased the mortality induced by CLP in septic mice ([@B13], [@B46]). In mice with lipopolysaccharide-induced ARDS, levels of IL-17A were elevated in plasma, lung tissue lysate, and bronchoalveolar lavage fluid ([@B60]). Consistently, patients with sepsis-induced ARDS show persisting high levels of IL-17A, suggesting that IL-17A is a biomarker to assess the severity and prognosis of diseases ([@B60]). Moreover, activation of the IL-23/IL-17 signaling produces harmful effects on sepsis-driven lung inflammation ([@B45]). Specifically, IL-17A expression, known to be induced by IL-23, is significantly increased in the lungs of septic mice induced by CLP ([@B45]). Neutralization of IL-17A ameliorates ALI and ARDS by modulating PI3K signaling and RORγt expression ([@B60]), suggesting that IL-17 could be explored as a therapeutic target for sepsis-associated ARDS.

### Immune Dysfunction or Immunosuppression

Sepsis disrupts immune homeostasis ([@B64]). A study in septic patients showed that inhibition of IL-17A by specific antibodies could lead to immune depression by increasing IL-10 release and decreasing IL-12 production from peripheral blood mononuclear cells ([@B57]).

A previous study reported that CD4^+^ T cells mediated abscess formation in intra-abdominal sepsis in an IL-17A-dependent manner ([@B35]). Similarly, IL-33, a potent immunoregulator, has been shown to attenuate sepsis by suppressing IL-17A-mediated signaling via upregulation of suppressor of cytokine signaling (SOCS)-3 ([@B52]).

Toxic shock syndrome caused by *Streptococcal* and *Staphylococcal* superantigens mimicks sepsis in clinical presentation. It is characterized by overexpression of proinflammatory cytokines and pathological immune responses ([@B53]). Overproduction of IL-17A was observed in the early phase of toxic shock syndrome; in contrast, anti-IL-17A antibodies obviously reduced intestinal and hepatic impairment and mortality rate ([@B53]).

### Acute Kidney Injury

Acute kidney injury (AKI) is the hallmark and a risk factor of sepsis; reversal of AKI correlates with lower risk of mortality ([@B89]). Several experimental and clinical studies support the importance of IL-17A secretion in AKI ([@B51]). Strikingly, IL-17A can function as a chemokine that recruits neutrophils to the kidneys ([@B55]).

IL-17A is associated with elevated levels of proinflammatory cytokines and accelerated tubular epithelial apoptosis in AKI ([@B51]). IL-17A is upregulated in animal models of acute tubular injury and cisplatin-induced AKI ([@B59]). In Th17 cells stimulated by heat-killed *C. albicans*, IL-17A levels significantly increased in patients with AKI after sepsis compared with healthy counterparts ([@B92]). In one study, Th17 cell activation was higher in patients who died from AKI following sepsis than in survivors, and the extent of activation correlated with AKI-associated inflammation ([@B93]). IL-17A knockdown can mitigate interstitial neutrophil infiltration and tubular impairment ([@B51], [@B59]). The intracellular receptor RORγt is required for IL-17A production, and RORγt deficiency protects against cisplatin-induced nephrotoxicity ([@B92]). IL-17A induces neutrophil migration through CXCL5, a chemokine known to be associated with higher risk of renal damage. Interestingly, high IL-17C expression has been noted in kidney epithelial cells following fungal infection ([@B6]), whereas lack of IL-17C in mice was associated with lower renal damage and improved survival ([@B78]). Altogether, the evidence supports that IL-17-induced responses potentiate AKI in septic patients.

### Gut Barrier Dysfunction

Intestinal mucosa dysfunction remains a challenge in the management of sepsis ([@B64]). Sepsis-induced gut barrier dysfunction includes disrupted mucosal integrity, increased permeability of the epithelial lining, impairment of gut-blood barrier, and bacterial translocation ([@B90]).

IL-17A is important in maintaining the integrity of epithelial barriers ([@B8]). IL-17A-mediated pathological responses disrupt intestinal epithelial barrier function, increase gut permeability, and cause translocation of gut bacteria by inhibiting proliferation of enterocytes and inducing their apoptosis ([@B8], [@B9]). Disseminated gram-positive bacteria can upregulate IL-17A by activating Toll-like receptor (TLR)-2 on T cells and dendritic cells ([@B47]). Neutralizing IL-17 in septic mouse models protects gut barrier integrity, reduces systemic inflammation and bacterial dissemination, and lowers mortality ([@B41]).

### Cardiomyocyte Dysfunction

Cardiomyocyte dysfunction is a complication that contributes to high mortality in sepsis patients ([@B90]). The molecular mechanisms underlying sepsis-induced cardiomyopathy are not well defined, but may involve a combination of endothelial disturbance, autonomic nervous system alterations, dysfunction of calcium regulation, oxidative and mitochondrial stress, extensive inflammation, and myocardial ischemia and reperfusion (I/R) injury ([@B90]). Up to now, no efficient treatment for sepsis-induced cardiomyopathy exists.

IL-17A levels are greatly increased in post-myocardial I/R injury, inflammation, and apoptotic responses ([@B94]). IL-17A accelerates the release of chemokines and proinflammatory mediators from fibroblasts, endothelial cells, leukocytes, and neutrophils ([@B95]). In viral myocarditis, neutralizing IL-17A with a monoclonal antibody attenuates myocardium inflammation, clinical symptoms, and disease progression ([@B96]). Knockdown of IL-17A in mice greatly mitigates cardiac disturbance as well as myocardial I/R injury and remodeling ([@B97]). Anti-IL-17A antibodies downregulate CCL3, CXCL1, and IL-6 in cardiomyocytes of mice with sepsis induced by CLP, suggesting that IL-17A contributes to sepsis-induced cardiomyopathy ([@B96]). Interestingly, high mobility group box-1 protein (HMGB1), a crucial late biomarker of lethal systemic inflammation in sepsis, stimulates IL-17A release during myocardial I/R injury ([@B98]). Conversely, HMGB1 inhibition remarkably lowers IL-17A levels and attenuates myocardial I/R injury ([@B98]). Therefore, the HMGB1/IL-17A axis may play a key role in myocardial dysfunction resulted from sepsis.

### Other Sepsis-Related Complications

Hepatic dysfunction is a prominent feature of sepsis with crucial implications for survival, since it contributes to sepsis-induced multiple organ failure ([@B89]). IL-17 from γδ T cells protects the host from *Listeria monocytogenes* infection by augmenting bacterial clearance through the liver ([@B67]). Absence of IL-17A or γδ T cells in mice is associated with greater bacterial load and inflammatory lesions in the liver ([@B67]). However, another study showed that IL-22, but not IL-17A, could protect hepatocytes from acute liver inflammation ([@B99]). The precise role of IL-17 in sepsis-induced hepatic damage remains unclear and requires deeper investigation.

The stress response following sepsis involves production of glucocorticoids and catecholamines ([@B90]). Both glucocorticoids and catecholamines inhibit the expression and production of IL-17A in lipopolysaccharide-stimulated peritoneal macrophages ([@B90]). They also block c-Jun-N-terminal kinase, preventing IL-17A secretion ([@B42]).

Taken together, excessive IL-17A production disrupts immune homeostasis and contributes to the development and progression of sepsis. Nevertheless, the exact contribution of IL-17 to sepsis-induced dysfunction of the liver and other organs needs to be further explored.

Administration of Exogenous IL-17 or Targeting IL-17 in Sepsis
--------------------------------------------------------------

IL-17A is an important link between the innate and adaptive immune processes ([@B43], [@B49]). IL-17A-deficient mice are more susceptible to sepsis than wild-type controls ([@B37]), and IL-17A blockade impairs peritoneal eradication of *E. coli*, indicating that IL-17A might prevent sepsis in certain settings ([@B63]). Consistent with this idea, IL-17A administration restores impaired immunity in CXCL1-knockout mice ([@B44]). In animals infected with *K. pneumoniae*, treatment with IL-17A promoted bacterial clearance and neutrophil recruitment by enhancing the production of G-CSF, IL-1β, TNF-α, and CXCL-2 ([@B36]). Likewise, IL-17A administration improved anti-bacterial immunity following challenge with group B *Streptococcus* and *Streptococcus pneumoniae* in mice ([@B34]). Neutralization of IL-17A promoted resistance to intra-abdominal abscess formation in mice challenged with *Bacteroides fragilis* or abscess-inducing zwitterionic polysaccharides ([@B35]). Neutralizing IL-17A with antibodies could also reduce the mortality of mice immunized with *S. aureus* iron regulated surface determinant B after bacterial challenge ([@B40]). Thus, IL-17A plays a pivotal role in prevention of infection progression and related infectious complications.

In agreement with the findings described above, inhibition of IL-17/IL-23 significantly improved survival (from 40 to 100%) in a mouse model of endotoxic shock ([@B39]). Likely, anti-IL-17A antibody reduces systemic levels of proinflammatory cytokines/chemokines and bacteremia, improving the survival rate ([@B50]). *E. coli* infection results in high levels of IL-17, and blockade of IL-17 attenuates neutrophil infiltration and improves bacterial clearance ([@B63]).

In a recent study, anti-IL-17 antibody mitigated the pathology and the mortality rate of mice infected with *Pseudomonas aeruginosa* ([@B100]). In a colitis mouse model, IL-17 neutralization attenuated immunopathology and bacteremia ([@B5]). In a neonatal sepsis mice model, treatment with IL-17A-neutralizing antibody mitigated IL-18-related disease deterioration ([@B57]). Targeting IL-17A enhanced IL-10 production in peripheral blood mononuclear cells following sepsis ([@B57]). This evidence supports the possibility of reducing sepsis mortality through antibody-mediated blockade of IL-17R or IL-17A ([Table 2](#T2){ref-type="table"}). Anti-IL-17A antibodies ixekizumab and secukinumab are currently being investigated in clinical trials in septic patients ([@B8], [@B9]).

###### 

Summary of studies on potential applications of IL-17 targeting in sepsis.

  **Years**   **Authors**      **Potential applications**                                                                                                                                                                                                **References**
  ----------- ---------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------
  2003        Tian et al.      Administration of a neutralizing antibody specific for IL-17A prevented abscess formation during bacterial challenge in mice                                                                                              ([@B35])
  2007        Shibata et al.   *In vivo* blockade of IL-17A significantly reduced neutrophil infiltration and impaired bacterial clearance in mice                                                                                                       ([@B36])
  2008        Flierl et al.    Neutralization of IL-17A *in vivo* reduced levels of systemic proinflammatory cytokines and chemokines, and bacteremia in mice                                                                                            ([@B37])
  2012        Joshi et al.     Neutralizing IL-17A *in vivo* significantly increased mortality in iron regulated *surface determinant B* immunized mice                                                                                                  ([@B40])
  2014        Jin et al.       Recombinant IL-17A rescued impaired host defense in *cxcl1^−/−^* mice; CXCL1 was important for IL-17A production via Th17 differentiation                                                                                 ([@B44])
  2015        Wu et al.        Treatment with anti-IL-17A enhanced IL-10 production but decreased IL-12 secretion from stimulated peripheral blood mononuclear cells of healthy controls and patients with severe sepsis                                 ([@B57])
  2015        Meng et al.      IL-17A neutralization protected barrier integrity and improves survival of septic mice                                                                                                                                    ([@B47])
  2016        Wynn et al.      Blocking IL-17A reduced IL-18-potentiated mortality to both neonatal sepsis and endotoxemia                                                                                                                               ([@B50])
  2016        Luo et al.       IL-17A knockout in mice could protect against sepsis-associated acute kidney injury                                                                                                                                       ([@B51])
  2017        Lv et al.        IL-33 attenuated sepsis by inhibiting IL-17 receptor signaling through upregulation of SOCS3 in mice                                                                                                                      ([@B29])
  2017        Szabo et al.     Rapid and rigorous IL-17A production by a distinct subpopulation of effector memory T lymphocytes constituted a novel mechanism of toxic shock syndrome immunopathology in mice                                           ([@B53])
  2017        Ding et al.      Increased IL-17A was observed in patients with sepsis-induced acute respiratory distress syndrome; IL-17 antibody administration could relieve acute lung injury symptoms by affecting RORγt level and the PI3K pathway   ([@B60])

Summary and Perspectives {#s4}
========================

IL-17A can regulate host defenses against invading pathogens by producing chemokines, AMPs, and proinflammatory cytokines. In this way, IL-17A forms part of the alarm signal by sentry-like immune cells to stimulate host defenses. On one hand, IL-17A interacts with various mediators (e.g., TNF-α, IL-1, IL-6) to induce tissue-infiltrating neutrophils to eliminate the invading pathogens. On the other hand, IL-17A may interact with other proinflammatory cytokines to drive exaggerated immune response, and contribute to the development of inflammatory and autoimmune diseases. There is burgeoning evidence that IL-17A participates in the pathophysiology of sepsis, with respect to regulation of inflammatory and immune responses. Consistently, elevated level of IL-17A is apparently related with disease severity in sepsis, suggesting a potential biomarker of prognosis in the clinical setting.

Moreover, developing IL-17A as a therapeutic target must consider the fact that IL-17A might be either protective or pathogenic, depending on the specific circumstances. Future work will be needed to deeply explore the pathophysiological mechanisms by IL-17A interfere with divergent immune responses during sepsis. In addition, studies are warranted to evaluate the other forms (IL-17B-IL-17F) in clinical settings.
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AMPs

:   antimicrobial peptides

APCs

:   antigen-presenting cells

C/EBP

:   CCAAT/enhancer-binding protein

CCL

:   chemokine (C-C motif) ligand

CXCL

:   C-X-C motif ligand

COX-2

:   cyclooxygenase-2

EBV

:   Epstein-Barr virus

GM-CSF

:   granulocyte-macrophage colony-stimulating factor

G-CSF

:   granulocyte-colony stimulating factor

HMGB1

:   high mobility group box-1 protein

IFN-γ

:   interferon-γ

IL

:   interleukin

iNOS

:   inducible nitric oxide synthase

iNKT-2

:   type 2 innate-like lymphoid cells

ILCs

:   innate lymphoid cells

I/R

:   ischemia and reperfusion

JAK

:   Janus kinase

MAPK

:   mitogen-activated protein kinase

NF-κB

:   nuclear factor-kappa B

NKT

:   natural killer T cell

PI3K

:   phosphatidylinostitol 3-kinase

PAMPs

:   pathogen-associated molecular patterns

RSV

:   respiratory syncytial virus

RORγt

:   RAR-related orphan receptor γ

SEFIR

:   SEF/IL-17R

STAT

:   signal transducers and activators of transcription

Th17

:   CD4^+^ T helper 17

TIR

:   Toll-IL-1 receptor

TRIF

:   TIR-domain-containing adapter-inducing interferon-β

TRAF

:   tumor necrosis factor receptor-associated factor

TNF-α

:   tumor necrosis factor-α

Th2

:   type 2 T helper

TSLP

:   thymic stromal lymphopoietin

MyD88

:   myeloid differentiation primary response gene 88.
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